secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2026-05-29T21:10:41+00:00
Accession:  0001213900-26-062935
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
--------------------------------------------------------------------------------

- Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.
- Must submit compliance plan by June 26, 2026; deadline to regain compliance by November 27, 2027.
- Company announced three ATNM-400 presentations at SNMMI 2026 (May 31-June 2) showing preclinical data in prostate cancer and NSCLC.
- If plan not accepted or compliance not regained, delisting proceedings will commence; no immediate effect on trading.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-062935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer